1. Economic Analysis of the TAX 317 Trial: Docetaxel Versus Best Supportive Care as Second-Line Therapy of Advanced Non–Small-Cell Lung Cancer
   Natasha B. Leighl et al, 2002, Journal of Clinical Oncology CrossRef